{
  "meta": {
    "publisher": "Mass Tort Marketing Agency",
    "dataset": "Cost Per Signed Retainer (CPR) Benchmark",
    "release": "2026-q1",
    "quarter": "Q1 2026",
    "temporalCoverage": "2026-01-01/2026-03-31",
    "dataAsOf": "2026-03-31",
    "published": "2026-04-24",
    "lastReviewed": "2026-06-10",
    "methodologyVersion": "1.0",
    "methodologyUrl": "https://www.masstortmarketingagency.com/benchmarks/methodology",
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/roundup",
    "verification": {
      "status": "unverified",
      "reviewer": null,
      "statement": "No third party has reviewed this methodology or the underlying data. Mass Tort Marketing Agency sells the leads these figures price."
    },
    "vendorDisclosure": "Mass Tort Marketing Agency sells the mass tort leads these figures price. The panel is the agency's own client base and the underlying performance data is self-reported by those firms.",
    "sourcesDisclosure": "Benchmark ranges are drawn from the panel performance data cross-referenced against published industry surveys and practitioner-disclosed benchmarks. Those sources are not named in the published methodology, and how they enter the calculation is not specified.",
    "license": {
      "name": "CC BY 4.0",
      "url": "https://creativecommons.org/licenses/by/4.0/",
      "attribution": "Mass Tort Marketing Agency CPR Benchmark, https://www.masstortmarketingagency.com/benchmarks/"
    },
    "nullConvention": "A null value is never a zero and never an estimate. Every null is paired with an adjacent *Reason field stating why the value is unavailable.",
    "snapshotUrl": "https://www.masstortmarketingagency.com/benchmarks/data/2026-q1.json"
  },
  "tort": {
    "slug": "roundup",
    "name": "Roundup (non-Hodgkin lymphoma)",
    "status": "Active",
    "cpr": {
      "low": 1400,
      "median": null,
      "medianUnavailableReason": "Per-tort medians are not published. The dataset carries the interquartile low and high bounds for each tort; only the national median is published as a point value.",
      "high": 2100,
      "currency": "USD"
    },
    "signedRatePct": {
      "low": 12,
      "high": 17
    },
    "qualificationTier": "Medium",
    "sampleSize": null,
    "sampleSizeUnavailableReason": "Per-tort sample sizes are not broken out in the published dataset. The panel total (140 firms, $180M of annual mass tort lead spend across 16 active tort categories) is published at the panel level only, so the number of firms and the spend basis behind any single row cannot be stated.",
    "confidenceInterval": null,
    "confidenceIntervalUnavailableReason": "Not computable from the published dataset. Benchmarks are published as trimmed interquartile ranges, and the per-observation values a confidence interval requires are not retained in the published figures.",
    "falloffPct": {
      "low": 12,
      "high": 15
    },
    "falloffUnavailableReason": null,
    "falloffNote": null,
    "rowUpdated": "2026-04-24",
    "rowUpdatedNote": "Rows are refreshed as a complete set each release, so every row carries the release publication date rather than an independent per-row date.",
    "qualificationCriteria": "Residential, agricultural, or commercial Roundup exposure plus a non-Hodgkin lymphoma diagnosis.",
    "statusAndAcquisition": "Active with mature inventory after nearly a decade of litigation. CPR stays low because criteria are broad and the acquisition funnel is well-optimized; Monsanto/Bayer settlement history creates favorable claimant awareness. Signed rate has been declining slowly as the most motivated claimants have already signed with competitor firms, so new entrants should model the lower end of the band (12%) rather than the upper end. Falloff is low because NHL diagnosis is medically well-documented and rarely reverses.",
    "relatedTorts": [
      "hair-relaxer",
      "camp-lejeune",
      "afff"
    ],
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/roundup",
    "quarter": "Q1 2026"
  },
  "series": {
    "low": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 1400,
        "valueReason": null
      }
    ],
    "high": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 2100,
        "valueReason": null
      }
    ]
  },
  "annotations": [
    {
      "id": "roundup-signed-rate-decline",
      "scope": "tort:roundup",
      "period": "2023-q1/2026-q1",
      "title": "Signed rate declined from 13% to 11%",
      "text": "The Roundup signed rate declined slowly from 13% in Q1 2023 to 11% in Q1 2026 as the most motivated claimants signed with competitor firms. Note that this stated 11% figure sits below the 12-17% signed-rate band published for Roundup in the Q1 2026 table; the source describes 12% as the level new entrants should model rather than the upper end of the band. The two figures are reproduced here as published and have not been reconciled.",
      "source": {
        "name": "Mass Tort Marketing Agency CPR Benchmark, Q1 2026 release",
        "url": "https://www.masstortmarketingagency.com/benchmarks/methodology/",
        "date": "2026-04-24",
        "type": "internal"
      }
    }
  ]
}